Mesenchymal Stem Cells in Regenerative Medicine for Musculoskeletal Diseases: Bench, Bedside, and Industry

Cell Transplantation

Review

Andrew Boyd Lin¹  Chih-Chang Wei²  Shih-Chieh Hung³ 

[1] Department of Biology, Case Western Reserve University, Cleveland, OH, USA;Stem Cell Laboratory, Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan;Stem Cell Laboratory, Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan;Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan;Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan;Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan;Institute of Pharmacology, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan;Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan;

关键词: Mesenchymal stem cells (MSCs);    Musculoskeletal diseases (MSDs);    Preclinical animal studies;    Clinical trials;    Industry;   

DOI  :  10.3727/096368914X678328

 received in 2013-10-30, accepted in 2014-01-29,  发布年份 2014

来源: Sage Journals

【 摘 要 】

Human bone marrow-derived mesenchymal stem cells (MSCs) can self-renew and differentiate into osteoblasts, chondrocytes, and adipocytes. MSCs have effectively emerged as a promising tool for clinical applications, specifically in musculoskeletal diseases. This article reviews the status of preclinical animal studies, clinical trials, and the efforts of the industry in using MSCs to treat musculoskeletal diseases such as bone fractures, bone defects, focal chondral lesions, osteoarthritis, spinal diseases, and tendon injuries. We also discuss the current problems encountered and potential of using MSCs in future clinical studies.

【 授权许可】

Unknown   
© 2014 Cognizant Comm. Corp.